GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abeona Therapeutics Inc (NAS:ABEO) » Definitions » Net Debt Paydown Yield %

Abeona Therapeutics (Abeona Therapeutics) Net Debt Paydown Yield % : -1.23% (As of May. 24, 2024)


View and export this data going back to 1980. Start your Free Trial

What is Abeona Therapeutics Net Debt Paydown Yield %?

Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt. As of today, Abeona Therapeutics's Net Debt Paydown Yield % was -1.23%.


Abeona Therapeutics Net Debt Paydown Yield % Historical Data

The historical data trend for Abeona Therapeutics's Net Debt Paydown Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abeona Therapeutics Net Debt Paydown Yield % Chart

Abeona Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Debt Paydown Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.25 1.24 -0.61 1.72

Abeona Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Debt Paydown Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.53 1.14 2.09 1.72 -1.06

Competitive Comparison of Abeona Therapeutics's Net Debt Paydown Yield %

For the Biotechnology subindustry, Abeona Therapeutics's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Abeona Therapeutics's Net Debt Paydown Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Abeona Therapeutics's Net Debt Paydown Yield % distribution charts can be found below:

* The bar in red indicates where Abeona Therapeutics's Net Debt Paydown Yield % falls into.



Abeona Therapeutics Net Debt Paydown Yield % Calculation

Abeona Therapeutics's Net Debt Paydown Yield % for the quarter that ended in Mar. 2024 is calculated as:

Net Debt Paydown Yield %
=( TTM Average Debt   (1-Year Ago))-TTM Average Debt )/Market Cap
=( 7.94-10.06 )/199.74185
=-1.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.


Abeona Therapeutics  (NAS:ABEO) Net Debt Paydown Yield % Explanation

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.

In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.

We calculating the TTM average debt by adding up the total debt, calculated by the sum of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation, in the trailing twelve months(TTM) divided by the counts of the total debt, accoring to the company's report frequency.


Abeona Therapeutics Net Debt Paydown Yield % Related Terms

Thank you for viewing the detailed overview of Abeona Therapeutics's Net Debt Paydown Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Abeona Therapeutics (Abeona Therapeutics) Business Description

Traded in Other Exchanges
Address
1330 Avenue of the Americas, 33rd Floor, New York, NY, USA, 10019
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its lead clinical programs consist of EB-101, autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, adeno-associated virus-based gene therapy for Sanfilippo syndrome type A, and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B.
Executives
Mark Alvino director C/O SCO SECURITIES LLC, 1285 AVENUE OF THE AMERICAS 35TH FLOOR, NEW YORK NY 10019
Michael Amoroso officer: Chief Operating Officer 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Faith L. Charles director ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Vishwas Seshadri director, officer: Chief Executive Officer 64 STRYKER COURT, BRIDGEWATER NJ 08807
Leila Alland director C/O PMV PHARMACEUTICALS, INC., 8 CLARKE DRIVE, SUITE 3, CRANBURY NJ 08512
Christine Berni Silverstein officer: Chief Financial Officer C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Joseph Walter Vazzano officer: Chief Financial Officer 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Brendan M. O'malley officer: SVP, General Counsel 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Adage Capital Partners, L.p. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Management, L.p. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Adage Capital Partners Gp, L.l.c. 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Robert Atchinson 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Phillip Gross 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Edward Carr officer: Vice President, Controller 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Todd Wider director 4848 LEMMON AVENUE, SUITE 517, DALLAS TX 75219